High-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma: A Multicenter, International Data-Sharing American Joint Committee on Cancer Study.


Journal

Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443

Informations de publication

Date de publication:
08 2022
Historique:
received: 30 01 2022
revised: 20 03 2022
accepted: 08 04 2022
pubmed: 19 4 2022
medline: 27 7 2022
entrez: 18 4 2022
Statut: ppublish

Résumé

To determine the value of clinical features for advanced intraocular retinoblastoma as defined by the eighth edition of the American Joint Committee on Cancer (AJCC) cT3 category and AJCC Ophthalmic Oncology Task Force (OOTF) Size Groups to predict the high-risk pathologic features. International, multicenter, registry-based retrospective case series. Eighteen ophthalmic oncology centers from 13 countries over 6 continents shared evaluations of 942 eyes enucleated as primary treatment for AJCC cT3 and, for comparison, cT2 retinoblastoma. International, multicenter, registry-based data were pooled from patients enrolled between 2001 and 2013. High-risk pathologic features were defined as AJCC categories pT3 and pT4. In addition, AJCC OOTF Size Groups were defined as follows: (1) less than half, (2) more than half but less than two thirds, (3) more than two thirds of globe volume involved, and (4) diffuse infiltrating retinoblastoma. Statistical risk of high-risk pathologic features corresponding to AJCC cT3 subcategories and AJCC OOTF Size Groups. Of 942 retinoblastoma eyes treated by primary enucleation, 282 (30%) showed high-risk pathologic features. Both cT subcategories and AJCC OOTF Size Groups (P < 0.001 for both) were associated with high-risk pathologic features. On logistic regression analysis, cT3c (iris neovascularization with glaucoma), cT3d (intraocular hemorrhage), and cT3e (aseptic orbital cellulitis) were predictive factors for high-risk pathologic features when compared with cT2a with an odds ratio of 2.3 (P = 0.002), 2.5 (P = 0.002), and 3.3 (P = 0.019), respectively. Size Group 3 (more than two-thirds globe volume) and 4 (diffuse infiltrative retinoblastoma) were the best predictive factors with an odds ratio of 3.3 and 4.1 (P < 0.001 for both), respectively, for high-risk pathologic features when compared with Size Groups 1 (i.e., < 50% of globe volume). The AJCC retinoblastoma staging clinical cT3c-e subcategories (glaucoma, intraocular hemorrhage, and aseptic orbital cellulitis, respectively) as well as the AJCC OOTF Size Groups 3 (tumor more than two thirds of globe volume) and 4 (diffuse infiltrative retinoblastoma) both allowed stratification of clinical risk factors that can be used to predict the presence of high-risk pathologic features and thus facilitate treatment decisions.

Identifiants

pubmed: 35436535
pii: S0161-6420(22)00284-6
doi: 10.1016/j.ophtha.2022.04.006
pmc: PMC9329269
mid: NIHMS1814230
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

923-932

Subventions

Organisme : NCI NIH HHS
ID : K08 CA232344
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Références

J Pediatr Hematol Oncol. 2021 Aug 1;43(6):e841-e847
pubmed: 33769386
Int J Ophthalmol. 2017 Jun 18;10(6):961-967
pubmed: 28730089
Br J Ophthalmol. 2015 Oct;99(10):1366-71
pubmed: 25873648
Eur J Ophthalmol. 2019 Mar;29(2):262-268
pubmed: 29890860
Ophthalmology. 2015 Jun;122(6):1165-72
pubmed: 25841975
Ophthalmol Retina. 2020 Jun;4(6):630-639
pubmed: 32387053
Ophthalmology. 2020 Dec;127(12):1719-1732
pubmed: 32512116
JAMA Ophthalmol. 2022 Jan 01;140(1):30-36
pubmed: 34762098
Ophthalmology. 2021 May;128(5):740-753
pubmed: 33007338
Ophthalmology. 2006 Dec;113(12):2276-80
pubmed: 16996605
J Pediatr Hematol Oncol. 2009 May;31(5):325-9
pubmed: 19415010
Pediatr Blood Cancer. 2013 Apr;60(4):688-93
pubmed: 22997170
JAMA Ophthalmol. 2016 May 01;134(5):584-591
pubmed: 26986443
Int Ophthalmol Clin. 2015 Winter;55(1):77-96
pubmed: 25436495
Ophthalmol Clin North Am. 2005 Mar;18(1):41-53, viii
pubmed: 15763190
Surv Ophthalmol. 2002 Jan-Feb;47(1):1-16
pubmed: 11801265
Ophthalmology. 2014 May;121(5):1109-18
pubmed: 24589388
Indian J Ophthalmol. 2018 Dec;66(12):1833-1838
pubmed: 30451190
Pediatr Blood Cancer. 2012 Mar;58(3):356-61
pubmed: 21721113
JAMA Oncol. 2020 May 1;6(5):685-695
pubmed: 32105305
Ophthalmology. 2020 Dec;127(12):1733-1746
pubmed: 32526306
J Clin Oncol. 2019 Nov 1;37(31):2883-2891
pubmed: 31539297
Ophthalmology. 2019 Sep;126(9):1306-1314
pubmed: 30986443
Lancet Glob Health. 2022 Mar;10(3):e307-e308
pubmed: 35093203
Saudi J Ophthalmol. 2013 Jul;27(3):147-50
pubmed: 24227979

Auteurs

Ankit Singh Tomar (AS)

Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York.

Paul T Finger (PT)

Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York. Electronic address: pfinger@eyecancer.com.

Brenda Gallie (B)

The Eye Cancer Clinic, Princess Margaret Cancer Centre, and Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Canada.

Tero T Kivelä (TT)

Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Ashwin Mallipatna (A)

The Eye Cancer Clinic, Princess Margaret Cancer Centre, and Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Canada; Department of Ocular Oncology, Narayana Nethralaya Eye Hospital, Bangalore, India.

Chengyue Zhang (C)

Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China.

Junyang Zhao (J)

Pediatric Oncology Center, Beijing Children's Hospital, Beijing, China.

Matthew W Wilson (MW)

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Rachel C Brennan (RC)

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Michala Burges (M)

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Jonathan Kim (J)

USC Roski Eye Institute, Keck Medical School, University of Southern California, and The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.

Jesse L Berry (JL)

USC Roski Eye Institute, Keck Medical School, University of Southern California, and The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.

Rima Jubran (R)

USC Roski Eye Institute, Keck Medical School, University of Southern California, and The Vision Center at Children's Hospital Los Angeles, Los Angeles, California.

Vikas Khetan (V)

Department of Vitreoretina Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Suganeswari Ganesan (S)

Department of Vitreoretina Services, Sankara Nethralaya, Chennai, Tamil Nadu, India.

Andrey Yarovoy (A)

Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation.

Vera Yarovaya (V)

Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation.

Elena Kotova (E)

Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation.

Denis Volodin (D)

Ocular Oncology Department, The S.N. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation.

Yacoub A Yousef (YA)

Department of Surgery (Ophthalmology), King Hussein Cancer Center, Amman, Jordan.

Kalle Nummi (K)

Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Tatiana L Ushakova (TL)

SRI of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation; Department of Ophthalmology, Medical Academy of Postgraduate Education, Moscow, Russian Federation.

Olga V Yugay (OV)

SRI of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation.

Vladimir G Polyakov (VG)

SRI of Pediatric Oncology and Hematology, N.N. Blokhin National Medical Research Center Oncology of Russian Federation, Moscow, Russian Federation; Department of Ophthalmology, Medical Academy of Postgraduate Education, Moscow, Russian Federation.

Marco A Ramirez-Ortiz (MA)

Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

Elizabeth Esparza-Aguiar (E)

Department of Ophthalmology, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

Guillermo Chantada (G)

Precision Medicine Coordination Hospital JP Garrahan, and CONICET, National Scientific and Technical Research Council, Buenos Aires, Argentina; Hemato-Oncology Service, Hospital Sant Joan de Déu, Barcelona, Spain.

Paula Schaiquevich (P)

Precision Medicine Coordination Hospital JP Garrahan, and CONICET, National Scientific and Technical Research Council, Buenos Aires, Argentina.

Adriana Fandino (A)

Ophthalmology Service, Hospital JP Garrahan, Buenos Aires, Argentina.

Jason C Yam (JC)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong.

Winnie W Lau (WW)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong.

Carol P Lam (CP)

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong.

Phillipa Sharwood (P)

Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, University of Sydney, Sydney, Australia.

Sonia Moorthy (S)

KK Women's and Children's Hospital, Singapore, Republic of Singapore.

Quah Boon Long (QB)

KK Women's and Children's Hospital, Singapore, Republic of Singapore.

Vera Adobea Essuman (VA)

Ophthalmology Unit, Department of Surgery, University of Ghana Medical School, College of Health Sciences, University of Ghana, Accra, Ghana.

Lorna A Renner (LA)

Department of Child Health, University of Ghana Medical School, College of Health Sciences, University of Ghana, Accra, Ghana.

Ekaterina Semenova (E)

Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center, New York, New York.

Jaume Català-Mora (J)

Retinoblastoma Unit, Department of Ophthalmology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.

Genoveva Correa-Llano (G)

Retinoblastoma Unit, Department of Ophthalmology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.

Elisa Carreras (E)

Retinoblastoma Unit, Department of Ophthalmology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH